Aurinia: Fourth Quarter Financial Results Overview

Aurinia Pharmaceuticals Reports Strong Fourth Quarter Results

Aurinia Pharmaceuticals Inc., headquartered in Edmonton, Alberta, announced earnings of $210.8 million for the fourth quarter.

The company’s net profit amounted to $1.53 per share, with adjusted earnings—excluding pretax gains—coming in at 26 cents per share.

These figures exceeded analyst expectations, as the consensus from three Zacks Investment Research analysts had predicted earnings of 21 cents per share.

Quarterly revenue reached $77.1 million, outperforming the anticipated $74.4 million from analysts surveyed by Zacks.

For the full year, Aurinia reported a total profit of $287.2 million, or $2.07 per share, with annual revenue totaling $283.1 million.

The company projects its revenue for the upcoming year to fall between $315 million and $325 million.

Since the start of the year, Aurinia’s stock price has declined by 9.5%, but over the past twelve months, shares have risen by 80%.